PHILADELPHIA, May 30, 2023
/PRNewswire/ -- Carisma Therapeutics Inc. (Nasdaq: CARM) ("Carisma"
or the "Company"), a clinical stage biopharmaceutical company
focused on discovering and developing innovative immunotherapies,
today announced that the Company will present at several healthcare
industry conferences in June 2023.
These conferences include:
2023 American Society of Clinical Oncology (ASCO) Annual
Meeting
- Yara Abdou, MD, will present
trials in progress poster during the meeting:
-
- A phase 1, first-in-human (FIH) study of autologous macrophages
engineered to express an anti-HER2 chimeric antigen receptor (CAR)
in participants (pts) with HER2-overexpressing solid tumors
-
- Saturday, June 3, 2023, at
8:00 am CT
- Chicago, Illinois
2023 Fierce Biotech Next Gen Virtual Event
- Michael Klichinsky, Pharm.D.,
Ph.D., Co-Founder & Chief Scientific Officer will give a
presentation on Carisma's revolutionary CAR-M approach.
-
- Tuesday, June 13, 2023 at
10:00 am ET
- Virtual
- Register to view webcast here.
CHI's Immuno-Oncology Summit Europe
- Tom Wilton, Chief Business
Officer, will give a presentation titled "CAR-M: Driving Anti-Tumor
Immunity with Chimeric Antigen Receptor Macrophages."
-
- Wednesday, June 21, 2023, at
5:10 pm BST
- London, United Kingdom
The Cell and Gene Therapy Conference
- Michael Klichinsky, Pharm.D.,
Ph.D., Co-Founder & Chief Scientific Officer will give a
presentation titled "Development of CAR macrophages – a novel
approach for solid tumor immunotherapy."
-
- Saturday, June 24, 2023 at
2:30 pm ET
- King of Prussia,
Pennsylvania
A replay of webcasts, when available, will be posted and
archived at Carisma's Investor Events webpage for a limited time
following the event.
About Carisma
Carisma Therapeutics Inc. is a clinical
stage biopharmaceutical company focused on utilizing our
proprietary macrophage and monocyte cell engineering platform to
develop transformative immunotherapies to treat cancer and other
serious diseases. We have created a comprehensive, differentiated
proprietary cell therapy platform focused on engineered macrophages
and monocytes, cells that play a crucial role in both the innate
and adaptive immune response. The first applications of the
platform, developed in collaboration with the University of Pennsylvania, are autologous chimeric
antigen receptor (CAR)-macrophages for the treatment of solid
tumors. Carisma is headquartered in Philadelphia, PA. For more information, please
visit www.carismatx.com.
Cautionary Note on Forward-Looking
Statements
Statements in this press release about future
expectations, plans and prospects, as well as any other statements
regarding matters that are not historical facts, may constitute
"forward-looking statements" within the meaning of The Private
Securities Litigation Reform Act of 1995. These statements include,
but are not limited to, statements relating to Carisma's business,
strategy, future operations, cash runway, the advancement of
Carisma's product candidates and product pipeline, and clinical
development of Carisma's product candidates, including expectations
regarding timing of initiation and results of clinical trials, and
participation by Carisma in future healthcare industry and investor
conferences. The words ""anticipate," "believe," "contemplate,"
"continue," "could," "estimate," "expect," "goals," "intend,"
"may," "might," "outlook," "plan," "project," "potential,"
"predict," "target," "possible," "will," "would," "could,"
"should," and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words.
Any forward-looking statements are based on management's current
expectations of future events and are subject to a number of risks
and uncertainties that could cause actual results to differ
materially and adversely from those set forth in, or implied by,
such forward-looking statements. For a discussion of these risks
and uncertainties, and other important factors, any of which could
cause Carisma's actual results to differ from those contained in
the forward-looking statements, see the "Risk Factors" set forth in
Exhibit 99.3 to Company's Current Report on Form 8-K filed with the
Securities and Exchange Commission on March
8, 2023, as well as discussions of potential risks,
uncertainties, and other important factors in Carisma's most recent
filings with the Securities and Exchange Commission. Any
forward-looking statements that are made in this press release
speak as of the date of this press release. Carisma undertakes no
obligation to revise the forward-looking statements or to update
them to reflect events or circumstances occurring after the date of
this press release, whether as a result of new information, future
developments or otherwise, except as required by the federal
securities laws.
Media Contact:
Julia Stern
(763) 350-5223
jstern@realchemistry.com
Investor Contact:
investors@carismatx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/carisma-therapeutics-to-present-at-upcoming-healthcare-industry-conferences-in-june-2023-301837732.html
SOURCE Carisma Therapeutics Inc.